- Drug therapy of overactive bladder - What is coming next?
-
Andersson
- KMID: 2344109
- Korean J Urol.
- 2015 Oct;56(10):673-679.
- doi: 10.4111/kju.2015.56.10.673
After the approval and introduction of mirabegron, tadalafil, and botulinum toxin A for treatment of lower urinary tract symptoms/overactive bladder, focus of interest has been on their place in therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Persistence and compliance with medication management in the treatment of overactive bladder
-
Kim TH, Lee KS
- KMID: 2363129
- Investig Clin Urol.
- 2016 Mar;57(2):84-93.
- doi: 10.4111/icu.2016.57.2.84
Overactive bladder (OAB) is a common and chronic condition that impacts patients' daily activities and quality of life. Pharmaco-therapy for OAB is a mainstay of treatment. Antimuscarinics and beta3-adrenoceptor agonists... -
- CITED
-
- Close
- SHARE
-
- Close
- NGF and HB-EGF: Potential Biomarkers that Reflect the Effects of Fesoterodine in Patients with Overactive Bladder Syndrome
-
Kim SR, Moon YJ, Kim SK, Bai SW
- KMID: 2352808
- Yonsei Med J.
- 2015 Jan;56(1):204-211.
- doi: 10.3349/ymj.2015.56.1.204
PURPOSE: To determine whether levels of nerve growth factor (NGF) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) can be used to objectively assess overactive bladder syndrome (OAB) treatment outcome... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Tolerability of Anticholinergics in Korean Children with Overactive Bladder: A Multicenter Retrospective Study
-
Park SJ, Pai KS, Kim JM, Park K, Kim KS, Song SH, Park S, Kim SO, Ryu DS, Baek M, Lee SD, Lee JW, Im YJ, Han SW, Chung JM, Cho MH, Ha TS, Cho WY, Suh HJ, The Korean Children's Continence and Enuresis Society
- KMID: 2069938
- J Korean Med Sci.
- 2014 Nov;29(11):1550-1554.
- doi: 10.3346/jkms.2014.29.11.1550
We investigated the efficacy and tolerability of various anticholinergics in Korean children with non-neurogenic overactive bladder (OAB). A total of 326 children (males:females= 157:169) aged under 18 yr (mean age... -
- CITED
-
- Close
- SHARE
-
- Close
